MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyTumor ProgressionCancer Cell SignalingCancer Molecular PathologyCancer ProgressionLung CancerMalignant NeoplasmsSignal Transduction In CancerChi-square TestDual-luciferase AssaysLuciferase Reporter AssaysMicrorna Regulation In CancerProtein Expression LevelsQuantitative Polymerase Chain ReactionQuantitative Polymerase Chain Reaction AssaysWestern Blot Analysis
BACKGROUND The aim of this study was to clarify the potential function of LINC00922 in regulating the progression of lung cancer and its underling mechanism. MATERIAL AND METHODS Relative levels of LINC00922 in lung cancer tissues and cell lines was determined by quantitative polymerase chain reaction. Correlation between LINC00922 levels and pathological indexes of lung cancer patients was analyzed through the chi-square test. Subsequently, regulatory effects of LINC00922 on the proliferative, migratory, and invasive capacities of PC9 and A549 cells were evaluated. Western blot was conducted to determine the role of LINC00922 in mediating protein levels of CXCR4, E-cadherin, and vimentin. Through dual-luciferase reporter gene assay and functional experiments, the potential function of LINC00922/miRNA-204/CXCR4 regulatory loop in mediating the progression of lung cancer was explored. RESULTS LINC00922 was highly expressed in lung cancer and correlated to the poor prognosis of lung cancer patients. Overexpression of LINC00922 accelerated PC9 and A549 cells to proliferate, migrate, and invade. CXCR4 was upregulated in lung cancer tissues and cells, which promoted lung cancer cells to migrate and invade. LINC00922 regulated the level of CXCR4 and directly bound to miRNA-204/CXCR4. LINC00922 mediated the cellular behaviors of lung cancer cells via targeting the miRNA-204/CXCR4 axis. CONCLUSIONS LINC00922 was upregulated in lung cancer, and accelerated lung cancer cells to proliferate, migrate, and invade via targeting the miRNA-204/CXCR4 axis.
34
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?
Leonardo Salmena, Laura Poliseno, Yvonne Tay et al. · Cell · 2011 · 7.7K citations · Full text
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
RNA Maps Reveal New RNA Classes and a Possible Function for Pervasive Transcription
Philipp Kapranov, Jill Cheng, Sujit Dike et al. · Science · 2007 · 2.6K citations
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations